Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation

BACKGROUND: The generation of data capturing the risk-benefit ratio of incorporating carboplatin (Cb) to neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) in a clinical practice setting is urgently needed. Tumour-infiltrating lymphocytes (TILs) have an established role in TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieci, Maria Vittoria, Carbognin, Luisa, Miglietta, Federica, Canino, Fabio, Giorgi, Carlo Alberto, Cumerlato, Enrico, Amato, Ottavia, Massa, Davide, Griguolo, Gaia, Genovesi, Elisa, Garufi, Giovanna, Giannarelli, Diana, Tornincasa, Antonio, Trudu, Lucia, Michieletto, Silvia, Saibene, Tania, Lo Mele, Marcello, Fassan, Matteo, Zarrilli, Giovanni, Piacentini, Federico, Bria, Emilio, Guarneri, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902542/
https://www.ncbi.nlm.nih.gov/pubmed/36396818
http://dx.doi.org/10.1038/s41416-022-02050-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902542/
https://www.ncbi.nlm.nih.gov/pubmed/36396818
http://dx.doi.org/10.1038/s41416-022-02050-8

Ejemplares similares